7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,884.90

-146.50

-3.63%

77,319.35

+100.92

+0.13%

Crude Oil Dec 26

102.95

+0.95

+0.93%

US Private Equity

10,850.63

-82.20

-0.75%

HKSE - Delayed Quote HKD

Akeso, Inc. (9926.HK)

81.500 -2.000 (-2.40%)

At close: October 30 at 4:08:07 PM GMT+8

Loading Chart for 9926.HK

Chart Range Bar

Interval:

In partnership with ChartIQ

Anthropic’s historic IPO; Akeso’s big clinical showing

Anthropic’s historic IPO; Akeso’s big clinical showing

Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab

Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab

Is Akeso (SEHK:9926) A Bargain Following Its New Phase III Colon Cancer Trial?

Is Akeso (SEHK:9926) A Bargain Following Its New Phase III Colon Cancer Trial?

First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer

First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer

Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026

Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026

Akeso (SEHK:9926) Stock Still Looks Cheap Despite Its 141% Run

Akeso (SEHK:9926) Stock Still Looks Cheap Despite Its 141% Run

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China

Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC

Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC

Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's

Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's

SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

Akeso logs Phase III success in second tumour type for ivonescimab

Akeso logs Phase III success in second tumour type for ivonescimab

Mobilize your Website

View Site in Mobile | Classic

Share by: